The UK and US have established a landmark trade agreement that will ensure no import taxes on UK medicine exports entering the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost spending on medicines through the public health system. This commitment ensures that import taxes on these crucial goods will remain at nothing for a period of 36 months.
This development follows earlier warnings to hike duties on branded drug products, with increases discussed reaching 100%.
"This agreement with the UK bolsters the international landscape for cutting-edge drugs and introduces long-overdue balance to U.S.–U.K. pharmaceutical trade," a statement declared.
Commercial Significance
Medicines are one of the UK's most significant goods shipped to the US, which is by far the largest destination for major companies like GSK and AstraZeneca.
Statistics show that in the year leading up to last September, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that span.
"This guarantee safeguards work, increases funding and facilitates the UK to emerge as a international leader for medical research," a minister stated.
Detailed NHS Changes
The agreement includes several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must pay back to the NHS to control costs will be limited at 15%. Previously, repayments topped twenty percent.
Recent Tensions
The deal takes place against a long-running tension between the pharmaceutical industry and the ministers over drug pricing and approval rates.
These tensions were exacerbated by arguments that US customers were paying several times more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or cancelled, while multi-billion-dollar investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the last ten years.
